More on PRME
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $3.22 |
|
|||
| Open | $3.15 | ||||
| 52 Wk High | $21.72 | ||||
| 52 Wk Low | $18.36 | ||||
| Day High | $3.22 | ||||
| Day Low | $3.08 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 3,349,457 | ||||
- H.C. Wainwright Reiterates Buy Rating on Prime Medicine (PRME)
- TD Cowen on Prime Medicine (PRME): 'We continue to view PRME as undervalued for the platform’s potential'
- BofA Securities Comments on Beam Therapeutics Inc (BEAM) Amid Selloff
- Form 8-K Prime Medicine, Inc. For: Jul 06
- Prime Medicine wins arbitration against Beam Therapeutics over PM647
- Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics
- H.C. Wainwright Upgrades Prime Medicine (PRME) to Buy
- FDA grants RMAT designation to Prime Medicine's CGD therapy PM359
- Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
- Prime Medicine (PRME) Reiterated at Market Outperform by Citizens as Trial Announced
Entities mentioned with PRME
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- FDA | View Related Stories »
- IPO | View Related Stories »
- Definitive Agreement | View Related Stories »
- Jefferies & Co | View Related Stories »
- Earnings | View Related Stories »
- Show More...
